Seattle Genetics, Inc. is a global biotechnology company that discovers, develops, and commercializes transformative medicines targeting cancer to make a meaningful difference in people’s lives. ADCETRIS® (brentuximab vedotin) and PADCEV™ (enfortumab vedotin-ejfv) use the company’s industry-leading antibody-drug conjugate (ADC) technology. Our ADC co-development agreements with Astellas and Genmab provide Seattle Genetics with opportunities to supplement our internal pipeline through opt-in rights to 50:50 co-development and profit-sharing for ADC product candidates. Under these collaborations, we are co-developing enfortumab vedotin with Astellas and tisotumab vedotin with Genmab. We are developing brentuximab vedotin in collaboration with Takeda Pharmaceutical Company. Learn how Seattle Genetics leads antibody-drug conjugate (ADC) research in treating cancer with meaningful efficacy while minimizing side effects. Seattle Genetics’ ADC technology combines the specificity of monoclonal antibodies, innovative linker systems and potent cell-killing agents to treat cancer.

The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE when internalized into CD30-expressing cells, resulting in target cell death. Ladiratuzumab vedotin is an antibody-drug conjugate (ADC) that we are developing for the treatment of breast cancer. -Seattle Genetics’ ADC Technology Featured in More Than 15 Presentations- -Multiple Preclinical Data Presentations Highlight Novel ADC Technology Advances and Support Program Development Plans- Apr. The technology has been licensed to several companies, including Genentech and GlaxoSmithKline. Under the terms of these agreements, each company has rights to use the technology with antibodies against selected targets. Seattle Genetics is dedicated to improving patient outcomes with advanced antibody-drug conjugate technology delivering cancer-killing therapy to tumor cells. Most metastatic breast cancers express LIV-1, which also has been detected in a number of other cancers, including melanoma, prostate, ovarian, uterine, and cervical cancers. Development Collaboration.